Adebrelimab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData, Phase II drugs for Bile Duct Cancer (Cholangiocarcinoma) have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Adebrelimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Adebrelimab (Ariely) is a humanized anti PD-L1 monoclonal antibody, acts as an anti-neoplastic agent. It is formulated as solution for intravenous route of administration. Ariely is indicated for the treatment of small cell lung cancer.
Adebrelimab (SHR-1316) is under development for the treatment of advanced malignancy, solid tumors including non-small cell lung cancer, small cell lung cancer, esophageal squamous cell cancer, nasopharyngeal carcinoma, hepatocellular carcinoma, pancreatic cancer, metastatic pancreatic cancer, intrahepatic cholangiocarcinoma, cervical cancer and non-small cell lung carcinoma. The drug candidate is administered through intravenous route. The drug candidate is a humanized IgG4 monoclonal antibody that acts by targeting PD-L1.
Jiangsu Hengrui Medicine overview
Jiangsu Hengrui Medicine (Jiangsu Hengrui) is a biopharmaceutical company that focuses on the research, development, manufacture, and distribution of novel pharmaceutical products. Its product portfolio includes anti-tumor drugs, surgical drugs, contrast agents, angiomyocardiac drugs, and antibiotics. The company is also developing pipeline products for the treatment of cancer, Crohn’s disease, anemia, diabetes, atopic dermatitis, chronic bone disease, blood pressure, and hypercholesterolemia. Jiangsu Hengrui has R&D facilities in China, the US, and Japan. The company offers products through its sales and distribution network in China, the US, Japan, Germany Switzerland, and Australia. Jiangsu Hengrui is headquartered in Lianyungang, Jiangsu Province, China.
For a complete picture of Adebrelimab’s drug-specific PTSR and LoA scores, buy the report here.